Primary care diabetes, Journal Year: 2023, Volume and Issue: 17(5), P. 506 - 512
Published: June 13, 2023
Language: Английский
Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 29(Suppl), P. S32 - S42
Published: Dec. 15, 2022
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of worldwide. The estimated global incidence NAFLD 47 cases per 1,000 population and higher among males than females. prevalence adults 32% (40%) compared to females (26%). has increased over time, from 26% in studies 2005 or earlier 38% 2016 beyond. varies substantially by world region, contributed differing rates obesity, genetic socioeconomic factors. exceeds 40% the Americas South-East Asia. projected increase significantly multiple regions 2030 if current trends are left unchecked. In this review, we discuss future projections.
Language: Английский
Citations
328
Alimentary Pharmacology & Therapeutics, Journal Year: 2022, Volume and Issue: 56(6), P. 942 - 956
Published: July 26, 2022
Summary Background The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing in parallel with obesity and type 2 diabetes. Aim To review the global epidemiology NAFLD Methods We retrieved articles from PubMed using search terms NAFLD, epidemiology, prevalence, incidence, comorbidities. Results Over 250 were reviewed. In 2016, was 25%; this increased to >30% 2019. Prevalence Asia, Latin America Middle East‐North Africa (MENA) 30.8%, 34.5% 42.6%, respectively. age. Although higher men, post‐menopausal women similar. certain subpopulations, especially among obese those metabolic syndrome (MS). However, lean 11.2%. steatohepatitis (NASH) estimated between 2% 6% general population. Approximately 7% patients have advanced fibrosis; rates 21% 50% NASH. Overall mortality related 15–20 per 1000 person‐years, substantially NASH, components MS. Recent data suggest mortality/morbidity globally but awareness remains low healthcare providers. Conclusions poses a public health problem very high burden MENA America. Research needed better quantify full impact develop strategies improve risk stratification.
Language: Английский
Citations
142
Nutrition, Journal Year: 2022, Volume and Issue: 105, P. 111847 - 111847
Published: Sept. 13, 2022
Language: Английский
Citations
50
World Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 29(1), P. 126 - 143
Published: Jan. 3, 2023
The metabolic syndrome as a consequence of the obesity pandemic resulted in substantial increase prevalence metabolic-associated fatty live disease (MAFLD) and type 2 diabetes mellitus (T2DM). Because similarity pathobiology shared between T2DM MAFLD, both disorders coexist many patients may potentiate disease-related outcomes with rapid progression increased complications individual diseases. In fact, awareness about this coexistence risk are often overlooked by hepatologists diabetologists. Management these patient should be addressed wholistically using an appropriate multidisciplinary team approach involving specialists and, when necessary, liaising dieticians surgeons. This comprehensive review is to compile current evidence from diabetologist's perspective on MAFLD suggest optimal management strategies.
Language: Английский
Citations
34
Cancers, Journal Year: 2024, Volume and Issue: 16(6), P. 1214 - 1214
Published: March 20, 2024
The prevalence of metabolic-associated fatty liver disease (MAFLD) is increasing globally due to factors such as urbanization, obesity, poor nutrition, sedentary lifestyles, healthcare accessibility, diagnostic advancements, and genetic influences. Research on MAFLD HCC risk factors, pathogenesis, biomarkers has been conducted through a narrative review relevant studies, with focus PubMed Web Science databases exclusion criteria based article availability language. Steatosis marks the early stage MASH advancement, commonly associated metabolic syndrome obesity type 2 diabetes. Various mechanisms, including heightened lipolysis, hepatic lipogenesis, consumption high-calorie diets, contribute accumulation lipids in liver. Insulin resistance pivotal development steatosis, it leads release free acids from adipose tissue. Natural compounds hold promise regulating lipid metabolism inflammation combat these conditions. Liver fibrosis serves significant predictor progression development, underscoring need target treatment approaches. Risk for MASH-associated encompass advanced fibrosis, older age, male gender, syndrome, predispositions, dietary habits, emphasizing requirement efficient surveillance measures. Considering important further studies determine biochemical impact order establish targeted therapies that can prevent or reduce MASH, indirectly decreasing HCC.
Language: Английский
Citations
15
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1589 - 1589
Published: Feb. 13, 2025
Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic (MASLD), is the most prevalent disorder globally, linked obesity, type 2 diabetes, and cardiovascular risk. Understanding its potential progression from simple steatosis cirrhosis hepatocellular carcinoma (HCC) crucial for patient management treatment strategies. The disease's complexity requires innovative approaches early detection personalized care. Omics technologies-such genomics, transcriptomics, proteomics, metabolomics, exposomics-are revolutionizing study of MASLD. These high-throughput techniques allow a deeper exploration molecular mechanisms driving progression. Genomics can identify genetic predispositions, whilst transcriptomics proteomics reveal changes in gene expression protein profiles during evolution. Metabolomics offers insights into alterations associated with MASLD, while exposomics links environmental exposures MASLD pathology. By integrating data various omics platforms, researchers map out intricate biochemical pathways involved This review discusses roles technologies enhancing understanding highlights diagnostic therapeutic targets within spectrum, emphasizing need non-invasive tools staging development.
Language: Английский
Citations
1
The Lancet Regional Health - Americas, Journal Year: 2024, Volume and Issue: 33, P. 100731 - 100731
Published: April 19, 2024
Liver disease is a major cause of mortality and morbidity worldwide its epidemiology depends on the genetic background, exposure to risk factors, access healthcare other sociodemographic characteristics. Brazil large country with diverse multicultural ethnic heritages important socioeconomic inequalities. The burden liver in Brazil, regions population unknown.
Language: Английский
Citations
6
Annals of Hepatology, Journal Year: 2022, Volume and Issue: 28(2), P. 100876 - 100876
Published: Nov. 16, 2022
Most epidemiological data on hepatocellular carcinoma (HCC) originate from resource-rich countries. We have previously described the epidemiology of HCC in South America through American Liver Research Network. Here, we provide an update changing continent seven years since that report.We evaluated all cases diagnosed between 2019 to 2021 centers six countries America. A templated, retrospective chart review patient characteristics at time diagnosis, including basic demographic, clinical and laboratory data, was completed. Diagnosis made radiologically or histologically for via institutional standards.Centers contributed a total 339 cases. Peru accounted 37% (n=125) patients; Brazil 16% (n=57); Chile 15% (n=51); Colombia 14% (n=48); Argentina 9% (n=29); Ecuador (n=29). The median age diagnosis 67 (IQR 59-73) 61% were male. most common risk factor nonalcoholic fatty liver disease (NAFLD, 37%), followed by hepatitis C (17%), alcohol use disorder (11%) B (12%). majority HCCs occurred setting cirrhosis (80%). HBV-related younger compared other causes, with 46 36-64).We report dramatic changes over last decade, substantial increase NAFLD-related HCC. still occurs much when causes.
Language: Английский
Citations
24
Annals of Hepatology, Journal Year: 2023, Volume and Issue: 29(3), P. 101175 - 101175
Published: Nov. 3, 2023
Liver disease poses a substantial burden in Latin America. This is primarily attributed to high level of alcohol consumption and the increasing prevalence risk factors associated with metabolic dysfunction-associated steatotic liver (MASLD), such as sedentary lifestyles, easy access ultra-processed foods, obesity, type 2 diabetes mellitus. These epidemiological trends are cause for concern, especially considering that there significant challenges addressing them, due disparities screening care. In this article, we aim provide an overview current situation regarding We also discuss recent multinational proposals designed address growing MASLD via its integration into existing non-communicable diseases policies, at both local global levels. Additionally, emphasize urgent need establish effective public health policies target excessive consumption. Furthermore, development transplantation programs, areas improvement medical education research capabilities, how fostering extensive collaboration among all stakeholders crucial region.
Language: Английский
Citations
12
The Lancet Regional Health - Americas, Journal Year: 2023, Volume and Issue: 28, P. 100633 - 100633
Published: Nov. 18, 2023
Healthcare systems in Latin America are broadly heterogeneous, but all of them burdened by a dramatic rise liver disease. Some challenges that these countries face include an increase patients requiring transplant, insufficient rates organ donation, delayed referral, and inequitable or suboptimal access to transplant programs post-transplant care. This could be improved expanding the donor pool through implementation education for citizens referring physicians, as well inclusion extended criteria donors, living donors split transplantation. Addressing shortcomings will require national shifts aimed at improving infrastructure, increasing awareness training medical personnel, providing equitable care patients.
Language: Английский
Citations
11